Pain Affecting Patents (Class 514/18.3)
-
Patent number: 8748387Abstract: The invention provides agents useful for treating pain. An exemplary agent comprises or consists of the a portion of a retroviral Tat protein. One such agent is the peptide Tat-NR2B9c. This peptide has previously been described as an agent for inhibiting damaging effects of stroke and similar conditions via inhibition of PSD95 interactions with NMDA receptors and/or NOS. The present application provides data showing that the Tat-NR2B9c peptides is effective in alleviation of pain. The alleviation of pain can be obtained at a dose of the peptide below the dose required to inhibit PSD-95 interactions with NMDAR or NOS.Type: GrantFiled: November 13, 2012Date of Patent: June 10, 2014Assignee: NoNO Inc.Inventors: Michael P. Belmares, Jonathan David Garman, Peter S. Lu, Michael W. Salter, Michael Tymianski
-
Patent number: 8748384Abstract: The present invention provides agents for inhibiting binding of a pro-neurotrophin to a Vps1 Op-domain receptor, in particular the binding of a pro-NGF or a pro-BDNF to a Sortilin receptor. The invention thus provides agents for the manufacture of a medicament, for treating and/or preventing disease or disorders such as but not limited to neurological, neuropsychiatric and ocular diseases, disorders, and degeneration as well as obesity, diabetes, pain and/or nociception in an individual.Type: GrantFiled: December 21, 2007Date of Patent: June 10, 2014Assignee: H. Lundbeck A/SInventors: Olav Michael Andersen, Anders Nykjaer
-
Patent number: 8729027Abstract: Disclosed is a drug effective in the treatment of fibromyalgia. Basically, the disclosed therapeutic agent was created on the basis of experiments showing improvement in symptoms when etanercept was administered to patients suffering from fibromyalgia. Etanercept is known as a therapeutic agent for rheumatoid arthritis, and the JFIQ score of patients not suffering from fibromyalgia improved considerably in the preferred embodiment. In other words, a therapeutic agent for fibromyalgia is disclosed that contains etanercept as an active ingredient in an effective amount.Type: GrantFiled: July 4, 2011Date of Patent: May 20, 2014Assignee: AXIS Inc.Inventor: Kusuki Nishioka
-
Patent number: 8716436Abstract: The invention relates to cyclic peptide agonists that bind to the mu (morphine) opioid receptor and their use in the treatment of acute and/or chronic pain. Embodiments of the invention are directed to cyclic pentapeptide and hexapeptide analogs of endomorphin that have (i) a carboxy-terminal extension with an amidated hydrophilic amino acid and (ii) a substitution in amino acid position 2. These peptide analogs exhibit decreased tolerance relative to morphine, increased solubility compared to similar tetrapeptide analogs, while maintaining favorable or improved therapeutic ratios of analgesia to side effects.Type: GrantFiled: May 22, 2012Date of Patent: May 6, 2014Assignees: The Administrators of the Tulane Educational Fund, U.S. Department of Veterans AffairsInventors: James E. Zadina, Laszlo Hackler
-
Publication number: 20140121168Abstract: TRPV1 antagonists and associated methods are provided. A TRPV1 channel antagonist can have the structure: Formula (I) wherein R1 can be —CH3, —(CH2)X(CH)YCH3 where x+y=1-20, an aromatic, a (CH2)n aromatic where n can be less than or equal to 6, a lipid, or a linker, and wherein R2 can be either Formula (II) or Formula (III) Additionally, R3 can be —O—R4 or —NH—R4 and R4 can be —H, —CH3, an ester, a cyclic ester, or an amide.Type: ApplicationFiled: April 26, 2012Publication date: May 1, 2014Applicant: ANTAGONISTS OF TRPV1 RECEPTORInventors: Eric Schmidt, Alan R. Light, Baldomero M. Olivera, Christopher A. Reilly, Zhejian Lin, Gisela P. Concepcion
-
Publication number: 20140107038Abstract: The present invention is directed to a method of producing analgesia in a mammalian subject. The method includes administering to the subject an omega conopeptide, preferably ziconotide, in combination with an analgesic selected from the group consisting of morphine, bupivacaine, clonidine, hydromorphone, baclofen, fentanyl 1, buprenorphine, and sufentanil, or its pharmaceutically acceptable salts thereof, wherein the ?-conopeptide retains its potency and is physically and chemically compatible with the analgesic compound. A preferred route of administration is intrathecal administration, particularly continuous intrathecal infusion. The present invention is also directed to a pharmaceutical formulation comprising an omega conopeptide, preferably ziconotide, an antioxidant, in combination with an analgesic selected from the group consisting of morphine, bupivacaine, clonidine, hydromorphone, baclofen, fentanyl, buprenorphine, and sufentanil.Type: ApplicationFiled: December 18, 2013Publication date: April 17, 2014Applicant: Jazz Pharmaceuticals International LimitedInventors: David J. ELLIS, George P. MILJANICH, David E. SHIELDS
-
Patent number: 8691764Abstract: The present invention provides a method for inhibiting NF-?B activity in a subject, the method comprising providing an agent capable of inducing expression of annexin 1, whereby said agent induces expression of annexin 1 and whereby said induced expression of annexin 1 inhibits NF-?B activity. Also provided are annexin 1 mimetics capable of binding to NF-?B and pharmaceutical compositions of such inducing and mimetic agents.Type: GrantFiled: March 28, 2008Date of Patent: April 8, 2014Assignee: The Research Foundation for the State University of New YorkInventors: Zhiquan Zhang, Basil Rigas
-
Patent number: 8691769Abstract: The present invention provides methods for treating sinus-evoked headaches using botulinum toxin injected or applied in multiple subcutaneous locations over divisions of the trigeminal nerve in soft tissues and dermatomes overlying the corresponding effected sinuses implicated in the etiology of the pain.Type: GrantFiled: March 8, 2004Date of Patent: April 8, 2014Assignee: Botulinum Toxin Research Associates, Inc.Inventors: Gary Borodic, Martin Andrew Acquadro
-
Publication number: 20140094415Abstract: The invention provides novel potent inhibitors of the ternary protein complex of nNOS, PSD-95, and the NMDA receptor and pharmaceutical compositions comprising the inhibitors for prophylaxis and/or treatment of excitotoxic-related disease and chronic pain conditions in a subject. The inhibitors are dimeric PSD-95 inhibitors comprising a first peptide or peptide analogue linked to a second peptide or peptide analogue by a linker, wherein the first and the second peptide or peptide analogue comprise at least four amide-bonded residues having a sequence YTXV or YSXV, wherein a. Y is selected from among E, Q, and A, or an analogue thereof, and b. X is selected from among A, Q, D, N,N-Me-A, N-Me-Q, N-Me-D, and N-Me-N or an analogue thereof, and wherein a Cell Penetrating Peptide (CPP) is linked to the linker or to an amino acid side chain of the first and second peptide or peptide analogue. The linker can be a PEG or NPEG linker.Type: ApplicationFiled: May 11, 2012Publication date: April 3, 2014Inventors: Anders Bach, Kristian Stromgaard
-
Publication number: 20140087993Abstract: Disclosed here is the rational design and use of potent and specific GPCR antagonist pepducins based on GPCR regions such as the third intracellular loop and adjacent regions.Type: ApplicationFiled: April 9, 2012Publication date: March 27, 2014Applicant: TUFTS MEDICAL CENTER, Inc.Inventors: Athan Kuliopulos, Lidija Covic
-
Patent number: 8679486Abstract: The present invention provides improved formulations of botulinum toxin that increase delivery of the botulinum toxin to neural and associated tissues and exhibit a higher specific neurotoxicity and higher potency (in LD50 Units) than available formulations of botulinum toxins. These improved formulations enable physicians to treat a wide variety of pathological conditions with a lower toxin load that reduces the risk of inducing an immune response against the toxin and its associated proteins that may ultimately lead to the development of toxin resistance. These benefits are particularly important in the treatment of conditions that require high-dose or chronic administration of botulinum toxin. Additionally, the decreased in LD50 Unit doses of inventive formulations allows for controlled administration limits diffusion. The present invention also provides methods of treating neuromuscular diseases and pain, using low-dose botulinum toxin.Type: GrantFiled: April 5, 2010Date of Patent: March 25, 2014Assignee: Botulinum Toxin Research Associates, Inc.Inventor: Gary E. Borodic
-
Publication number: 20140073577Abstract: Disclosed is a composition of matter comprising an isolated polypeptide, which is a peripherally-restricted Nav1.7 inhibitor. In some disclosed embodiments, the isolated polypeptide is an inhibitor of Nav1.7 and/or Nav1.3. Other embodiments are conjugated embodiments of the inventive composition of matter and pharmaceutical compositions containing the inventive composition of matter. Isolated nucleic acids encoding some embodiments of inventive polypeptides and expression vectors, and recombinant host cells containing them are disclosed. A method of treating or preventing pain is also disclosed.Type: ApplicationFiled: March 16, 2012Publication date: March 13, 2014Applicant: AMGEN INC.Inventors: Justin K. Murray, Leslie P. Miranda, Stefan I. McDonough
-
Publication number: 20140057845Abstract: In order to provide a composition for treating, improving, or preventing pain, it has been found out that a metallothionein protein is expressed in a normal peripheral nerve, and that the expression is not observed in a peripheral nerve producing pain. Moreover, it has been found out that administering metallothionein to rats having neuropathic pain suppresses the pain in the rats.Type: ApplicationFiled: February 23, 2012Publication date: February 27, 2014Applicant: SAPPORO MEDICAL UNIVERSITYInventors: Yasuo Kokai, Gousuke Ooki, Kayo Matsumoto, Shinichi Imai, Takuro Wada
-
Publication number: 20140051638Abstract: Botulinum toxin, among other presynaptic neurotoxins is used for the treatment and prevention of migraine and other headaches associated with vascular disorders. Presynaptic neurotoxins are delivered focally, targeting the sphenopalatine ganglion. Exemplary delivery is carried out by way of injection.Type: ApplicationFiled: August 15, 2013Publication date: February 20, 2014Applicant: Allergan, Inc.Inventor: Andrew M. Blumenfeld
-
Patent number: 8653032Abstract: Disclosed is a pharmaceutical composition for preventing or treating TRPV1 activity-related or inflammation-related, diseases or conditions, containing a Maillard peptide separated from well-aged traditional soy sauce as an active ingredient. The Maillard peptide in the present invention functions both as a TRPV1 agonist and a TRPV1 antagonist, and further functions as a TRPV1 activity modulator. Therefore, the Maillard peptide can be used for preventing or treating TRPV1 activity-related diseases such as pain, neurological diseases, urgent defecation, inflammatory bowel disease, respiratory diseases, urinary incontinence, overactive bladder, neurogenic / allergic / inflammatory skin diseases, skin, eye or mucosal irritation, hyperacusis, tinnitus, vestibular hypersensitivity, heart disease, etc.Type: GrantFiled: November 8, 2010Date of Patent: February 18, 2014Assignees: Korea Food Research Institute, SNU R & DB FoundationInventors: Mee-Ra Rhyu, Ah-Young Song, Eun-Young Kim, Seog Bae Oh, YoungJoo Lee, Won Chung Lim
-
Patent number: 8653033Abstract: The present invention is directed to a method of producing analgesia in a mammalian subject. The method includes administering to the subject an omega conopeptide, preferably ziconotide, in combination with an analgesic selected from the group consisting of morphine, bupivacaine, clonidine, hydromorphone, baclofen, fentanyl, buprenorphine, and sufentanil, or its pharmaceutically acceptable salts thereof, wherein the ?-conopeptide retains its potency and is physically and chemically compatible with the analgesic compound. A preferred route of administration is intrathecal administration, particularly continuous intrathecal infusion. The present invention is also directed to a pharmaceutical formulation comprising an omega conopeptide, preferably ziconotide, an antioxidant, in combination with an analgesic selected from the group consisting of morphine, bupivacaine, clonidine, hydromorphone, baclofen, fentanyl, buprenorphine, and sufentanil.Type: GrantFiled: March 8, 2013Date of Patent: February 18, 2014Assignee: Jazz Pharmaceuticals International LimitedInventors: David J. Ellis, George P. Miljanich, David E. Shields
-
Publication number: 20140038881Abstract: Therapeutic peptides having guanylyl cyclase C agonist activity are disclosed. The therapeutic peptides are analogues of the E. coli STa peptide with non-natural amino acid, isosteric or D-amino acid substituents. The therapeutic peptides are useful in the treatment of chronic ideopathic constipation, inflammatory bowel disease, and other diseases. Pharmaceutical compositions comprising comprising the therapeutic peptides are also disclosed.Type: ApplicationFiled: June 8, 2011Publication date: February 6, 2014Applicant: COMBIMAB, INCInventors: Henry Wolfe, Reinhard Ebner
-
Patent number: 8642732Abstract: The following class of molecule is disclosed: a dimer containing a first neublastin polypeptide and a second neublastin polypeptide, wherein: (a) at least one of the polypeptides is glycosylated; (b) at least one of the polypeptides is conjugated at its N-terminus to a water-soluble synthetic polymer; and (c) neither of the polypeptides is conjugated to a water-soluble synthetic polymer at a position other than the N-terminus. Such dimers possess the biological activity of wild-type neublastin while displaying enhanced serum half-life and enhanced potency relative to wild-type neublastin.Type: GrantFiled: March 21, 2012Date of Patent: February 4, 2014Assignee: Biogen Idec MA Inc.Inventors: Dinah Wen-Yee Sah, R. Blake Pepinsky, Anthony Rossomando
-
Patent number: 8637031Abstract: Methods are disclosed for treating osteoarthritis in a human subject in need thereof, comprising administering to the subject a therapeutically effective amount of an anti-human NGF antibody, or antigen-binding fragment thereof, wherein at least one symptom associated with osteoarthritis is prevented, ameliorated or improved.Type: GrantFiled: October 10, 2012Date of Patent: January 28, 2014Assignee: Regeneron Pharmaceuticals, Inc.Inventors: Lynn MacDonald, Richard Torres, Marc R. Morra, Joel H. Martin, Joel C. Reinhardt, Paul Tiseo
-
Patent number: 8618045Abstract: Provided is a modified human tumor necrosis factor receptor-1 polypeptide or a fragment thereof that binds to a tumor necrosis factor in vivo or ex vivo. The modified human tumor necrosis factor receptor-1 polypeptide or fragment exhibits improved ability to bind tumor necrosis factor and resistance to proteases.Type: GrantFiled: December 21, 2011Date of Patent: December 31, 2013Assignee: Hanall Biopharma Co., Ltd.Inventors: Sung Wuk Kim, Sung Soo Jun, Seung Kook Park, Song Young Kim, Eun Sun Kim, Jae Kap Jeong, Ha Na Kim, Yeon Jung Song
-
Patent number: 8617569Abstract: A method for treating a patient with migraine headache includes administering to the patient a therapeutically effective amount of an invertebrate presynaptic neurotoxin in a pharmaceutically safe form. The administration includes extramuscular injection of the neurotoxin to emerging nerve points including foraminal sites for enabling neurotoxin access to concentrated nerve bundles at exit points of the foramina.Type: GrantFiled: May 23, 2012Date of Patent: December 31, 2013Inventor: William J. Binder
-
Patent number: 8613927Abstract: A human antibody or antigen-binding fragment of an antibody which specifically binds human nerve growth factor (NGF) with KD of 5 pM or less, as measured by surface plasmon resonance, wherein the antibody or fragment thereof binds human NGF with an affinity of about 2-10-fold higher than the antibody or fragment binds rat and mouse NGF. The antibodies are useful in treating pain, including inflammatory pain, post-operative incision pain, neuropathic pain, fracture pain, osteoporotic fracture pain, post-herpetic neuralgia, osteoarthritis, rheumatoid arthritis, cancer pain, pain resulting from burns, gout joint pain, as well as diseases, such as hepatocellular carcinoma, breast cancer, and liver cirrhosis.Type: GrantFiled: February 28, 2012Date of Patent: December 24, 2013Assignee: Regeneron Pharmaceuticals, Inc.Inventors: Lynn MacDonald, Richard Torres, Marc R. Morra, Joel H. Martin, Joel C. Reinhardt
-
Patent number: 8609810Abstract: The present invention relates to compounds which inhibit or antagonize the binding of methylglyoxal (MG) and/or other reactive carbonyl species (RCS) to an arginine- or lysine- containing protein, preferably an arginine- or lysine-containing cellular protein, such as a sodium ion channel, e.g. the sodium ion channel Na(v)1.8. Preferred scavenger compounds are peptides comprising several or multiple repeats of the amino acid sequence motif Gly-Glu-X-Pro (GEXP), wherein X is Arg or Lys, and pharmaceutical compositions thereof. The present invention furthermore relates to the use of the compounds as scavenger or antagonists of methylglyoxal and/or related reactive carbonyl species (RCS). The present invention furthermore relates to the use of the compounds for the prevention and/or treatment of pain, hyperalgesia and pain related diseases, in particular pain and/or hyperalgesia caused by or associated with methylglyoxal and/or reactive carbonyl species (RCS).Type: GrantFiled: May 26, 2010Date of Patent: December 17, 2013Assignee: Ruprecht-Karls-Universitat HeidelbergInventors: Peter Nawroth, Angelika Bierhaus, Thomas Fleming
-
Patent number: 8603983Abstract: Botulinum toxin, among other presynaptic neurotoxins is used for the treatment and prevention of migraine and other headaches associated with vascular disorders. Presynaptic neurotoxins are delivered focally, targeting the nerve endings of the trigeminal nerve, the occipital nerve and the intranasal terminals of the parasympathetic fibers originating in the Sphenopalatine ganglion. The administration preferably targets the extracranial nerve endings of the trigeminal nerve in the temporal area, the extracranial occipital nerve endings in the occipital area, and the intranasal terminals of the trigeminal nerve and parasympathetic fibers originating in the Sphenopalatine ganglion. The delivery is carried out by way of injection or topically.Type: GrantFiled: May 17, 2012Date of Patent: December 10, 2013Assignee: Allergan, Inc.Inventor: Andrew M. Blumenfeld
-
Publication number: 20130324475Abstract: A method and solution for perioperatively inhibiting a variety of pain and inflammation processes during arthroscopic procedures. The solution preferably includes a vasoconstrictor that exhibits alpha-adrenergic activity and one or more additional pain and inflammation inhibitory agents at dilute concentration in a physiologic carrier, such as saline or lactated Ringer's solution. The solution is applied by continuous irrigation of a wound during a surgical procedure for peripheral vasoconstriction and inhibition of pain and/or inflammation while avoiding undesirable side effects associated with systemic application of larger doses of the agents.Type: ApplicationFiled: May 13, 2013Publication date: December 5, 2013Applicant: Omeros CorporationInventors: Gregory A. Demopulos, Pamela Pierce Palmer, Jeffrey M. Herz
-
Publication number: 20130324462Abstract: The use of flagellin and flagellin related polypeptides for reducing cancer treatment side effects in mammals is described.Type: ApplicationFiled: March 26, 2013Publication date: December 5, 2013Inventors: Andrei V. Gudkov, Vadim Krivokrysenko, Lyudmila Burdelya
-
Patent number: 8598123Abstract: The present invention relates to compounds of Formula (I) and their pharmaceutically acceptable salts, wherein the substituents are as described herein, and their use in medicine, in particular as opioid agonists.Type: GrantFiled: September 7, 2012Date of Patent: December 3, 2013Assignee: Pfizer Inc.Inventors: Christopher Gordon Barber, Dafydd Rhys Owen, Lisa Rosemary Thompson
-
Publication number: 20130316953Abstract: The present invention is directed to the use of compounds of the formula: for treating pain, in particular neuropathic pain, bipolar disease and migraine headaches.Type: ApplicationFiled: July 29, 2013Publication date: November 28, 2013Applicant: RESEARCH CORPORATION TECHNOLOGIES, INC.Inventor: Robert H. Harris
-
Publication number: 20130310324Abstract: The present invention relates to Huwentoxin-IV variants, polynucleotides encoding them, and methods of making and using the foregoing.Type: ApplicationFiled: March 15, 2013Publication date: November 21, 2013Applicant: JANSSEN BIOTECH, INC.Inventors: Mack Flinspach, Michael Hunter, Yi Liu, Robert Neff, Alan Wickenden, Alan Gibbs
-
Publication number: 20130303459Abstract: The present invention relates to the use of Meteorin for the treatment of allodynia, hyperalgesia, spontaneous pain and phantom pain. In a preferred embodiment the disorder to be treated is allodynia, and hyperalgesia, more preferably allodynia including thermal and tactile allodynia.Type: ApplicationFiled: March 14, 2013Publication date: November 14, 2013Inventors: Jesper Roland Jørgensen, Lars Ulrik Wahlberg, Teit E. Johansen
-
Publication number: 20130281380Abstract: The disclosure herein relates to modified ?PKC inhibitory peptides, methods of generating such peptides, and method for using ?PKC inhibitory peptides for the treatment of pain.Type: ApplicationFiled: July 2, 2013Publication date: October 24, 2013Inventors: Derek Maclean, Qun Yin
-
Patent number: 8551949Abstract: The invention provides for methods and compositions for treatment of pain via craniofacial mucosal administration of an analgesic compound (e.g. a non-opioid analgesic peptide, an NOP agonist or N/OFQ). Intranasal administration of certain analgesic peptides such as N/OFQ results in global analgesic effects.Type: GrantFiled: July 27, 2010Date of Patent: October 8, 2013Assignee: Nocicepta LLCInventors: Lawrence R. Toll, David C. Yeomans, Martin S. Angst, Daniel I. Jacobs
-
Publication number: 20130252902Abstract: A method for treating a patient who has a neutralizing antibody to a type A1 botulinum toxin. The method includes administering 150 kDa type A neurotoxin from type A2 Clostridium botulinum (A2 NTX) to the patient. In accordance with the present invention, a problem can be solved of decrease in clinical response caused by a neutralizing antibody to a type A1 botulinum toxin produced when a patient is treated with a pharmaceutical preparation containing a type A1 botulinum toxin.Type: ApplicationFiled: May 28, 2013Publication date: September 26, 2013Applicant: THE CHEMO-SERO THERAPEUTIC RESEARCH INSTITUTEInventors: Shinji NAKAHIRA, Yasushi Torii, Yoshitaka Goto, Miho Shinmura, Satomi Munechika, Sachio Okuda, Shunji Kozaki
-
Publication number: 20130244947Abstract: Disclosed are compositions and methods related to improving pharmacological properties of bioactive compounds targeting nervous system.Type: ApplicationFiled: March 29, 2013Publication date: September 19, 2013Applicant: University of Utah Research FoundationInventors: Grzegorz Bulaj, H. Steve White
-
Patent number: 8536137Abstract: The present invention is directed to the use of a class of peptide compounds for treating tumor pain, in particular bone cancer pain, for treating chemotherapy-induced pain and for treating nucleoside-induced pain.Type: GrantFiled: October 12, 2009Date of Patent: September 17, 2013Assignee: UCB Pharma GmbHInventors: Bettina Beyreuther, Thomas Stöhr
-
Publication number: 20130236444Abstract: A method for treating a patient with migraine headache includes administering to the patient a therapeutically effective amount of an invertebrate presynaptic neurotoxin in a pharmaceutically safe form. The administration includes extramuscular injection of the neurotoxin to emerging nerve points including foraminal sites for enabling neurotoxin access to concentrated nerve bundles at exit points of the foramina.Type: ApplicationFiled: May 23, 2012Publication date: September 12, 2013Inventor: William J. BINDER
-
Patent number: 8530425Abstract: Botulinum toxin, among other presynaptic neurotoxins is used for the treatment and prevention of migraine and other headaches associated with vascular disorders. Presynaptic neurotoxins are delivered focally, targeting the sphenopalatine ganglion. Exemplary delivery is carried out by way of injection.Type: GrantFiled: June 13, 2011Date of Patent: September 10, 2013Assignee: Allergan, Inc.Inventor: Andrew M. Blumenfeld
-
Patent number: 8523569Abstract: The present invention relates to a method of delivering local anesthetic after dental extraction surgery. The present invention relates to packing the tooth socket with a tinned release local anesthetic which is coordinated with an initial local anesthetic and which lasts up to 5 days. The socket can be surgically sealed or the implant can act as the sealing means.Type: GrantFiled: December 22, 2008Date of Patent: September 3, 2013Inventor: Khashayar Kevin Neshat
-
Publication number: 20130225499Abstract: The present invention is directed to a method of producing analgesia in a mammalian subject. The method includes administering to the subject an omega conopeptide, preferably ziconotide, in combination with an analgesic selected from the group consisting of morphine, bupivacaine, clonidine, hydromorphone, baclofen, fentanyl, buprenorphine, and sufentanil, or its pharmaceutically acceptable salts thereof, wherein the ?-conopeptide retains its potency and is physically and chemically compatible with the analgesic compound. A preferred route of administration is intrathecal administration, particularly continuous intrathecal infusion. The present invention is also directed to a pharmaceutical formulation comprising an omega conopeptide, preferably ziconotide, an antioxidant, in combination with an analgesic selected from the group consisting of morphine, bupivacaine, clonidine, hydromorphone, baclofen, fentanyl, buprenorphine, and sufentanil.Type: ApplicationFiled: March 8, 2013Publication date: August 29, 2013Applicant: AZUR PHARMA INTERNATIONAL LIMITEDInventor: AZUR PHARMA INTERNATIONAL LIMITED
-
Publication number: 20130225500Abstract: The present invention provides an active peptide purified from scorpions, and derivatives, analogues and active fragment which are produced by using genetic engineering technology. The analgesic active peptide VGG is extracted, separated and purified from scorpion, and its amino acid sequence is shown as below: VKDGYIADDRNCPYFCGRNAYCDGECKKNRAESGYCQWASKYGNACWCY KLPDDARIMKPGRCNGG. The present invention further provides a use of the peptides in preparation of an analgesic drug, where the peptide is mixed with a pharmaceutically acceptable carrier to prepare into forms for injection, oral administration, transdermal absorption, and transmucosal absorption.Type: ApplicationFiled: July 5, 2011Publication date: August 29, 2013Applicant: SHENYANG PHARMACEUTICAL UNIVERSITYInventors: Jianhai Zhang, Zhou Yang, Yanfeng Liu, Chunfu Wu
-
Publication number: 20130217632Abstract: This invention relates in one aspect to non-natural desamino alkyl amino acid compounds, methods of making these compounds, and peptides containing these compounds. In one embodiment, the peptide is neurotensin (8-13) in which the N-terminus is an alpha-desamino, alpha-methyl-N,N-dimethyl-homolysine residue of the invention.Type: ApplicationFiled: March 4, 2013Publication date: August 22, 2013Applicant: MUSC Foundation for Research DevelopmentInventor: MUSC Foundation for Research Development
-
Patent number: 8513198Abstract: The present invention is directed to a method of producing analgesia in a mammalian subject. The method includes administering to the subject an omega conopeptide, preferably ziconotide, in combination with an analgesic selected from the group consisting of morphine, bupivacaine, clonidine, hydromorphone, baclofen, fentanyl, buprenorphine, and sufentanil, or its pharmaceutically acceptable salts thereof, wherein the ?-conopeptide retains its potency and is physically and chemically compatible with the analgesic compound. A preferred route of administration is intrathecal administration, particularly continuous intrathecal infusion. The present invention is also directed to a pharmaceutical formulation comprising an omega conopeptide, preferably ziconotide, an antioxidant, in combination with an analgesic selected from the group consisting of morphine, bupivacaine, clonidine, hydromorphone, baclofen, fentanyl, buprenorphine, and sufentanil.Type: GrantFiled: September 14, 2012Date of Patent: August 20, 2013Assignee: Jazz Pharmaceuticals International LimitedInventors: David J. Ellis, George P. Miljanich, David E. Shields
-
Publication number: 20130210740Abstract: Methods of inducing antinociception in a human are described. The method includes the step of administering an effective dose of a polypeptide comprising L-neo-tryptophan to the human extracranially. The polypeptide containing L-neo-tryptophan could be, but is not limited to, NT64L, NT65L, NT66L, NT67L, NT69L, NT69L?, NT71, NT72, NT73, NT74, NT75, NT76, or NT77.Type: ApplicationFiled: August 21, 2012Publication date: August 15, 2013Inventors: Elliott Richelson, Bernadette Marie Cusack, Yuan-Ping Pang, Daniel J. McCormick, Abdul Fauq, Beth Marie Tyler, Mona Boules
-
Patent number: 8507440Abstract: A method for managing withdrawal from an addictive substance is described. The method involves administering one or more peptides having specific activity for the ? and/or ? isozyme of protein kinase C (PKC). The peptide(s) can be administered prior to, concurrent with, or subsequent to administration of the addictive substance. Also described is a kit having at least one container containing a peptide having isozyme-specific activity for ?PKC or ?PKC and instructions for use.Type: GrantFiled: September 10, 2010Date of Patent: August 13, 2013Assignee: The Board of Trustees of the Leland Stanford Junior UniversityInventors: Daria Mochly-Rosen, Joan J. Kendig, Sarah M. Sweitzer
-
Publication number: 20130203678Abstract: In some aspects, the present invention provides methods of treating a subject in need of treatment for neuropathic pain, the method comprising administering a compstatin analog to the subject. In some embodiments, the compstatin analog is administered parenterally, e.g., intravenously.Type: ApplicationFiled: June 8, 2012Publication date: August 8, 2013Applicant: Apellis Pharmaceuticals, Inc.Inventors: Cedric Francois, Pascal Deschatelets
-
Publication number: 20130196923Abstract: The present invention relates to novel isolated peptides which induce analgesia and which inhibit ASIC channels (Acid Sensing Ion Channels), to the polynucleotides encoding said peptides, and also to the pharmaceutical compositions, host cells and vectors comprising same. In particular, said peptides are isolated from the venom of the snake Dendroaspis polylepis. The present invention also relates to the use thereof as a diagnostic tool or as medicament, and in particular as an analgesic, or for identifying analgesic molecules or molecules which inhibit ASIC channels.Type: ApplicationFiled: July 26, 2011Publication date: August 1, 2013Applicant: CENTRE NATIONAL DE LA RESERCHE SCIENTIFIQUE-CNRSInventors: Eric Lingueglia, Sylvie Diochot, Anne Baron-Forster, Miguel Salinas, Michel Lazdunski
-
Patent number: 8492336Abstract: There is disclosed an isolated nucleic acid molecule encoding a human neurotrophic growth factor designated enovin and having the amino acid sequence illustrated in FIG. 1, 21, 23 or 24 or encoding a functional equivalent, derivative or bioprecursor of said growth factor. The growth factor preferably comprises the amino acid sequence from position 27 to 139 of the sequence illustrated in FIG. 1, or a functional equivalent, derivative or bioprecursor thereof. The nucleic acid molecule encoding enovin can be used to transform a host cell, tissue or organism by including it in an appropriate vector. The host cell, tissue or organism and the vector also form part of the invention.Type: GrantFiled: December 21, 2010Date of Patent: July 23, 2013Assignee: Janssen Pharmaceutica N.V.Inventor: Stefano Leo Jozef Masure
-
Patent number: 8492346Abstract: The disclosure herein relates to modified ?PKC inhibitory peptides, methods of generating such peptides, and method for using ?PKC inhibitory peptides for the treatment of pain.Type: GrantFiled: September 12, 2011Date of Patent: July 23, 2013Assignee: KAI Pharmaceuticals, Inc.Inventors: Derek Maclean, Qun Yin
-
Publication number: 20130177576Abstract: The invention provides pharmaceutical compositions and methods of use thereof for preventing or ameliorating disorders of the nervous system. More specifically, the invention provides pharmaceutical compositions, including phosphopeptides, that when administered disrupt TrkB-mediated activation of PLC?1 phosphorylation. The invention further provides method of treatment comprising administering inhibitors of TrkB-mediated activation of PLC?1 phosphorylation alone or in combination with other pharmaceutical compositions to prevent or ameliorate nervous system disorders such as epilepsy, stroke, anxiety, migraine, and pain.Type: ApplicationFiled: March 7, 2013Publication date: July 11, 2013Applicant: DUKE UNIVERSITYInventor: DUKE UNIVERSITY
-
Publication number: 20130156704Abstract: The application provides data from a clinical trial of a PSD-95 inhibitor in subjects undergoing endovascular repair of an aneurysm in or otherwise affecting the CNS. The subjects were stratified by whether the aneurysm ruptured before performing the endovascular surgery. Rupture is associated with higher mortality or increased debilitation if a subject survives. The trial provided evidence of significant benefit in subjects with and without aneurysm rupture before endovascular was surgery performed. Surprisingly, the subjects benefiting most from treatment as judged both by pathology and neurocognitive outcome were those in which the aneurysm had ruptured causing a subarachnoid hemorrhage. These data constitute evidence that a PSD-95 inhibitor is beneficial not only in ischemic and hemorrhagic stroke but in forms of hemorrhage in or affecting the CNS, particularly, subarachnoid hemorrhage.Type: ApplicationFiled: February 22, 2013Publication date: June 20, 2013Applicant: NoNO Inc.Inventor: NoNO Inc.